The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

INNOVENT BIO (01801.HK)'s total product revenue for 2024 amounted to more than RMB8.2 billion, representing a robust YoY ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

There is potentially more competition for the incretin giants in the shape of Innovent’s mazdutide (licensed to Lilly for co-development). It’s unlikely to make a dent in the sales figures for the ...

Mazdutide is under clinical development by Eli Lilly and Co and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) ...

Key highlights include: As the company advances key cornerstone products in its pipeline, we are actively expanding the development of mazdutide, teprotumumab, and picankibart into additional ...

Key highlights include: As the company advances key cornerstone products in its pipeline, we are actively expanding the development of mazdutide, teprotumumab, and picankibart into additional ...

These include Bima for obesity, retatrutide for chronic kidney disease (CKD) with or without type 2 diabetes (T2D), eloralintide for obesity, and Mazdutide, also targeting obesity. Beyond the ...

This is also the fourth large-scale phase 3 clinical study of mazdutide. GLORY-2 plans to enroll 450 subjects and randomize to receive mazdutide 9 mg treatment or placebo. The primary endpoints ...